A Safety Study of ARRY-300 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

This is a Phase 1 study, involving a 1-day dosing period (up to 3 dosing periods per subject), designed to test the safety of investigational study drug ARRY-300 in healthy subjects. Approximately 12 healthy subjects from the US will be enrolled in this study.

Key facts

Study ID
NCT00828165
Run by
Array Biopharma, now a wholly owned subsidiary of Pfizer
People needed
12
Starts
2009-01-01
Expected to finish
2009-04-01
Last updated by the study team
2020-10-06

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.